This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded CTNM, CC, ACI, BRKR and SAFE; targets fell for CTNM, CC and ACI, while BRKR received a new $60 target.
Stocks · News reference
Jones Trading Maintains Buy on Contineum Therapeutics, Raises Price Target to $30
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Baird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14
Baird analyst Joel Beatty downgrades Contineum Therapeutics (NASDAQ:CTNM) from Outperform to Neutral and lowers the price target from $19 to $14.
Why Is Contineum Therapeutics Stock Falling Monday?
BMS trial results trigger a 29% drop in Contineum (CTNM), but analysts highlight long-term potential for PIPE-791 in IPF.